BCHT(SH:688276) Xin Lang Cai Jing·2025-10-10 01:28Group 1 - The core viewpoint of the news is that Baike Biological experienced a slight increase in stock price and notable trading activity, with significant financing and margin trading data indicating a mixed sentiment among investors [1] Group 2 - As of October 9, Baike Biological's stock price rose by 0.91%, with a trading volume of 46.96 million yuan. The financing buy-in amount was 8.80 million yuan, while the financing repayment was 9.24 million yuan, resulting in a net financing buy of -0.43 million yuan [1] - The total margin trading balance for Baike Biological reached 261 million yuan, with the financing balance accounting for 2.85% of the circulating market value, indicating a high level compared to the past year [1] - On the margin trading side, there were no shares repaid on October 9, with 9,399 shares sold short, amounting to 0.21 million yuan at the closing price. The short selling balance was 71,980 yuan, which is below the 30th percentile level over the past year, indicating a low level of short interest [1] Group 3 - As of June 30, Baike Biological had 10,100 shareholders, an increase of 0.40% from the previous period, with an average of 40,980 circulating shares per shareholder, a decrease of 0.40% [2] - For the first half of 2025, Baike Biological reported operating revenue of 285 million yuan, a year-on-year decrease of 53.93%, and a net profit attributable to shareholders of -73.57 million yuan, a decline of 153.47% [2] - Since its A-share listing, Baike Biological has distributed a total of 235 million yuan in dividends, with 194 million yuan distributed over the past three years [2] - As of June 30, 2025, among the top ten circulating shareholders, the Southern CSI 1000 ETF was the newest addition, holding 1.52 million shares, while the China National Bio-Medical Index A and Southern CSI 500 ETF exited the top ten list [2]